Daniel SW Tan: Highlights from the MOH Value based healthcare conference
Daniel SW Tan, at
“Attended the MOH Value based healthcare conference on Friday last week and was thrilled by the growing interest in Health Technology Assessments. Implementation and reimbursement of new technologies is a final, critical hurdle in drug development. Samantha Roberts Chief Executive, provided a contemporary overview of NICE, how they are evolving with the needs of health systems as well as emphasizing how HTA in a sense reflect needs and values of society.
Also grateful to DS Jasmin Lau for sharing perspectives around addressing the rising cost of healthcare in Singapore, trials and tribulations of the Cancer Drug List that has overall led to more affordable cancer drugs, and the longer term strategic shift to primary prevention through healthier SG and capitation.
As we anticipate the stage shift across cancers in the ensuing decade, there remains a need to facilitate biomarker-driven clinical trials and enable innovative mechanisms to access therapies, both of which continue to be key drivers of precision oncology both in early stage and metastatic setting.
Appreciate ACE and Daphne Khoo for organising this insightful conference and look forward to growing our academic HSR efforts! ”
Source: Daniel SW Tan/LinkedIn
